A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma.

Trial Profile

A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Siltuximab (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 11 Aug 2012 Additional trial location (Germany) added as reported by European Clinical Trials Database.
    • 16 Nov 2011 Actual initiation date (24 Feb 2011) added as reported by European Clinical Trials Database.
    • 28 Oct 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top